Antiverse
AI antibody discovery, Cardiff
Generative AI de novo antibody design for GPCRs and hard drug targets. It raised $9.3m in its Series A in March 2026. It has 1 role open, 1 of them in the UK.
On the Home Office register of licensed visa sponsors.
- 122 daystypical age of an open role
- 1roles open for more than 60 days
- 0roles taken down since we started tracking
- 0%of roles list a salary
Open roles
1 live today- Salary not listed3 Jul 2026Apply
Open roles over time
Hiring momentum
Roles per weekNo data yet.
Open roles by function
Open roles by team
As the company labels themIn the news
All 9 stories- FundingHealthcare Today, 19 Mar 2026Antiverse raises $9.3 million Series A
- OtherBioCentury, 11 Mar 2026Antiverse: Accessing hidden targets with AI design and cell engineering
- OtherCystic Fibrosis News Today, 10 Mar 2026Antiverse, Cystic Fibrosis Foundation team to develop new antibodies
- Otherpharmaphorum, 5 Mar 2026Welsh firm Antiverse raises funds for AI antibody platform
- OtherLewis Silkin, 4 Mar 2026Lewis Silkin has advised Innovation Investment Capital on its investment into Antiverse
- Otherpulse2.com, 3 Mar 2026Antiverse: $9.3 Million Raised For AI-Driven Antibody Development Targeting Undruggable Disease Targets